Ocular Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major ocular pain markets are expected to exhibit a CAGR of 7.9% during 2024-2034.
The ocular pain market has been comprehensively analyzed in IMARC's new report titled "Ocular Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ocular pain refers to discomfort or distress experienced within or around the eye. It can differ in intensity, from mild irritation to severe throbbing. The symptoms of the ailment may include aching, burning, stinging, itching, or a feeling of pressure in and around the eye. Additionally, individuals suffering from the illness may also experience sensitivity to light, blurred vision, excessive tearing, or redness in the affected eye. This disease can result from a variety of factors, such as eye strain, dry eyes, allergies, infections, foreign objects in the eye, or underlying medical conditions like glaucoma or migraines. Diagnosing the cause of ocular pain typically involves a comprehensive eye examination by an ophthalmologist. The doctor will investigate the patient's medical history, perform visual acuity tests, and examine the eye's structures using specialized instruments. Additional tests, such as measuring intraocular pressure, evaluating tear production, or using imaging techniques like optical coherence tomography, may be conducted to determine the underlying issue.
The increasing incidences of prolonged reading, computer use, or numerous other activities that require intense visual focus, leading to eye strain and discomfort, are primarily driving the ocular pain market. In addition to this, the inflating utilization of efficacious treatments, such as topical non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, opioid analgesics, etc., to ameliorate symptoms and prevent further damage is creating a positive outlook for the market. Moreover, the widespread adoption of advanced diagnostic techniques like fundus photography, which aid in the timely detection and management of underlying eye conditions that may contribute to ocular pain, is also bolstering the market growth. Apart from this, the rising usage of laser therapies, such as selective laser trabeculoplasty for glaucoma or photodynamic therapy for certain retinal issues, that provide targeted relief from discomfort, is acting as another significant growth-inducing factor. These therapies aim to alleviate pressure and inflammation, thereby decreasing the sensation of pain in the affected eye region. Additionally, the emerging developments in the field of gene therapy, aiming to correct or replace the genetic triggers behind conditions causing ocular pain, are also augmenting the market growth. Furthermore, the escalating popularity of teleophthalmology services, which enable remote consultations and improve patient compliance, is expected to drive the ocular pain market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the ocular pain market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for ocular pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the ocular pain market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the ocular pain market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the ocular pain market
Reimbursement scenario in the market
In-market and pipeline drugs
This report also provides a detailed analysis of the current ocular pain marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report
Market Insights
How has the ocular pain market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the ocular pain market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the ocular pain market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of ocular pain across the seven major markets?
What is the number of prevalent cases (2018-2034) of ocular pain by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of ocular pain by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with ocular pain across the seven major markets?
What is the size of the ocular pain patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of ocular pain?
What will be the growth rate of patients across the seven major markets?
Ocular Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for ocular pain drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the ocular pain market?
What are the key regulatory events related to the ocular pain market?
What is the structure of clinical trial landscape by status related to the ocular pain market?
What is the structure of clinical trial landscape by phase related to the ocular pain market?
What is the structure of clinical trial landscape by route of administration related to the ocular pain market?
The ocular pain market has been comprehensively analyzed in IMARC's new report titled "Ocular Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ocular pain refers to discomfort or distress experienced within or around the eye. It can differ in intensity, from mild irritation to severe throbbing. The symptoms of the ailment may include aching, burning, stinging, itching, or a feeling of pressure in and around the eye. Additionally, individuals suffering from the illness may also experience sensitivity to light, blurred vision, excessive tearing, or redness in the affected eye. This disease can result from a variety of factors, such as eye strain, dry eyes, allergies, infections, foreign objects in the eye, or underlying medical conditions like glaucoma or migraines. Diagnosing the cause of ocular pain typically involves a comprehensive eye examination by an ophthalmologist. The doctor will investigate the patient's medical history, perform visual acuity tests, and examine the eye's structures using specialized instruments. Additional tests, such as measuring intraocular pressure, evaluating tear production, or using imaging techniques like optical coherence tomography, may be conducted to determine the underlying issue.
The increasing incidences of prolonged reading, computer use, or numerous other activities that require intense visual focus, leading to eye strain and discomfort, are primarily driving the ocular pain market. In addition to this, the inflating utilization of efficacious treatments, such as topical non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, opioid analgesics, etc., to ameliorate symptoms and prevent further damage is creating a positive outlook for the market. Moreover, the widespread adoption of advanced diagnostic techniques like fundus photography, which aid in the timely detection and management of underlying eye conditions that may contribute to ocular pain, is also bolstering the market growth. Apart from this, the rising usage of laser therapies, such as selective laser trabeculoplasty for glaucoma or photodynamic therapy for certain retinal issues, that provide targeted relief from discomfort, is acting as another significant growth-inducing factor. These therapies aim to alleviate pressure and inflammation, thereby decreasing the sensation of pain in the affected eye region. Additionally, the emerging developments in the field of gene therapy, aiming to correct or replace the genetic triggers behind conditions causing ocular pain, are also augmenting the market growth. Furthermore, the escalating popularity of teleophthalmology services, which enable remote consultations and improve patient compliance, is expected to drive the ocular pain market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the ocular pain market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for ocular pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the ocular pain market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the ocular pain market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the ocular pain market
Reimbursement scenario in the market
In-market and pipeline drugs
This report also provides a detailed analysis of the current ocular pain marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report
Market Insights
How has the ocular pain market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the ocular pain market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the ocular pain market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of ocular pain across the seven major markets?
What is the number of prevalent cases (2018-2034) of ocular pain by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of ocular pain by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with ocular pain across the seven major markets?
What is the size of the ocular pain patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of ocular pain?
What will be the growth rate of patients across the seven major markets?
Ocular Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for ocular pain drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the ocular pain market?
What are the key regulatory events related to the ocular pain market?
What is the structure of clinical trial landscape by status related to the ocular pain market?
What is the structure of clinical trial landscape by phase related to the ocular pain market?
What is the structure of clinical trial landscape by route of administration related to the ocular pain market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 OCULAR PAIN - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 OCULAR PAIN - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 OCULAR PAIN - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 OCULAR PAIN - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 OCULAR PAIN - UNMET NEEDS
10 OCULAR PAIN - KEY ENDPOINTS OF TREATMENT
11 OCULAR PAIN - MARKETED PRODUCTS
11.1 List of Ocular Pain Marketed Drugs Across the Top 7 Markets
11.1.1 Acular Ls (Ketorolac Tromethamine Ophthalmic Solution)- Allergan
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Nevanac (Nepafenac)- Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Inveltys (Loteprednol Etabonate Ophthalmic Suspension) - Alcon
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Dextenza (Dexamethasone Ophthalmic Insert) - Ocular Therapeutix
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Tyrvaya (Varenicline Solution) - Oyster Point Pharma
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 OCULAR PAIN - PIPELINE DRUGS
12.1 List of Ocular Pain Pipeline Drugs Across the Top 7 Markets
12.1.1 SAF312 - Novartis
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 SYL1001 - Sylentis
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 SURF-200 - Surface Ophthalmics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 APP13007 - Formosa Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 SDN-037 - Sun Pharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. OCULAR PAIN - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. OCULAR PAIN – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 OCULAR PAIN - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Ocular Pain - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Ocular Pain - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Ocular Pain - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Ocular Pain - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Ocular Pain - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Ocular Pain - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Ocular Pain - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Ocular Pain - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Ocular Pain - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Ocular Pain - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Ocular Pain - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Ocular Pain - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Ocular Pain - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Ocular Pain - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Ocular Pain - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Ocular Pain - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Ocular Pain - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Ocular Pain - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Ocular Pain - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Ocular Pain - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Ocular Pain - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Ocular Pain - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Ocular Pain - Access and Reimbursement Overview
16 OCULAR PAIN - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 OCULAR PAIN MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 OCULAR PAIN MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 OCULAR PAIN - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 OCULAR PAIN - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 OCULAR PAIN - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 OCULAR PAIN - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 OCULAR PAIN - UNMET NEEDS
10 OCULAR PAIN - KEY ENDPOINTS OF TREATMENT
11 OCULAR PAIN - MARKETED PRODUCTS
11.1 List of Ocular Pain Marketed Drugs Across the Top 7 Markets
11.1.1 Acular Ls (Ketorolac Tromethamine Ophthalmic Solution)- Allergan
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Nevanac (Nepafenac)- Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Inveltys (Loteprednol Etabonate Ophthalmic Suspension) - Alcon
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Dextenza (Dexamethasone Ophthalmic Insert) - Ocular Therapeutix
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Tyrvaya (Varenicline Solution) - Oyster Point Pharma
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 OCULAR PAIN - PIPELINE DRUGS
12.1 List of Ocular Pain Pipeline Drugs Across the Top 7 Markets
12.1.1 SAF312 - Novartis
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 SYL1001 - Sylentis
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 SURF-200 - Surface Ophthalmics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 APP13007 - Formosa Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 SDN-037 - Sun Pharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. OCULAR PAIN - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. OCULAR PAIN – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 OCULAR PAIN - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Ocular Pain - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Ocular Pain - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Ocular Pain - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Ocular Pain - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Ocular Pain - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Ocular Pain - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Ocular Pain - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Ocular Pain - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Ocular Pain - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Ocular Pain - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Ocular Pain - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Ocular Pain - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Ocular Pain - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Ocular Pain - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Ocular Pain - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Ocular Pain - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Ocular Pain - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Ocular Pain - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Ocular Pain - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Ocular Pain - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Ocular Pain - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Ocular Pain - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Ocular Pain - Access and Reimbursement Overview
16 OCULAR PAIN - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 OCULAR PAIN MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 OCULAR PAIN MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
